ABMD — Stock Film
STOCK FILMSCENE 1/11ABMD · $381
Stock Expert AI presents
ABMD
Abiomed, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Abiomed, Inc. A quick introduction.

On the stock market since 1987, it operates in the world of health and science. It has 2,003 employees. Now — the numbers.

on the stock market since 1987
2,003 employees
$17B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $13 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 13%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
95%Products
Products 95%Service and Other 5%
95% of all revenue comes from a single line: Products.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 15% a year over the last 4 years. Every year shown ended in profit.

$593.7M
2018
$769.4M
2019
$840.9M
2020
$847.5M
2021
$1B
2022
Cash on hand:
$0
Total debt:
$0
The cash outweighs the debt.

If every debt were paid off today, $758.6M would still be left in the vault — a solid cushion for hard times.

Every quarter, analysts set a profit bar.
How many of the last 6 did the company clear?
6 / 6
EXPECTATIONS MET OR BEATEN
6
Aug 2021
Oct 2021
Feb 2022
Apr 2022
Aug 2022
Nov 2022
6 TIMES IN THE LAST 6 QUARTERS
It clears the bar, quarter after quarter.
THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 10% a year on average.

2
THE BRIGHT SIDE · 2/3
Strong cash, light debt

There is $758.6M in the vault; even if every debt were paid off, $758.6M would remain.

3
THE BRIGHT SIDE · 3/3
Delivers on expectations

It met or beat analyst expectations in 6 of the last 6 quarters — consistency is a promise kept.

1
THE RISKS · 1/2
A rich price tag

The company’s market value is 126 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/2
Executives lean toward selling

Over the last 12 months, executives reported 84 sells against just 13 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, ABMD sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: ABMD is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film